Clincosm LogoSign in Get a demo

EIFI: Emerging Invasive Fungal Infections in Critically Ill Patients

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT04647539
Collaborator
(none)
26
Enrollment
1
Location
178.7
Actual Duration (Months)
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are increasing in intensive care setting and are associated with high morbidity and mortality. However, data are scarce, particularly in ICU settings and for EIFIs other than mucormycosis.

Objectives: to describe epidemiological trends and clinical features of EIFIs in intensive care units (ICU) and to assess their outcome.

Methods: All records of adult patients diagnosed with an EIFI in a medical ICU between 2006 and 2019 were analyzed retrospectively. In-ICU mortality was assessed, then factors associated with mortality were identified. Survival at day-90 was calculated by the Kaplan-Meier method.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    26 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Emerging Invasive Fungal Infections in Critically Ill Patients: Epidemiological Trends, Clinical Features and Outcomes
    Actual Study Start Date :
    Jan 1, 2006
    Actual Primary Completion Date :
    Dec 1, 2019
    Actual Study Completion Date :
    Nov 23, 2020

    Outcome Measures

    Primary Outcome Measures

    1. mortality [at ICU admission]

      mortality

    Secondary Outcome Measures

    1. Mucormycosis [at ICU admission]

      Mucormycosis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:
    • Adults (≥ 18 years old) with at least 1 positive culture for molds other than candida and aspergillosis
    Exclusion criteria:
    • Age < 18, pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uhmontpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Principal Investigator: Romaric Larcher, MD, PharmD, MSc, UH Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT04647539
    Other Study ID Numbers:
    • RECHMPL20_0626
    First Posted:
    Dec 1, 2020
    Last Update Posted:
    Dec 1, 2020
    Last Verified:
    Nov 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    Emergind invasive fungal infection
    mucormycosis
    ICU
    Additional relevant MeSH terms:
    Infections
    Communicable Diseases
    Mycoses
    Invasive Fungal Infections

    Study Results

    No Results Posted as of Dec 1, 2020